Clearmind Medicine (NASDAQ:CMND) Shares Down 0.8%

Clearmind Medicine Inc. (NASDAQ:CMND)’s stock price traded down 0.8% during trading on Thursday . The stock traded as low as $1.15 and last traded at $1.17. 45,654 shares were traded during trading, a decline of 96% from the average session volume of 1,239,950 shares. The stock had previously closed at $1.18.

Clearmind Medicine Stock Performance

The company has a current ratio of 1.96, a quick ratio of 1.96 and a debt-to-equity ratio of 0.01. The stock’s fifty day simple moving average is $1.27 and its two-hundred day simple moving average is $2.27.

Clearmind Medicine (NASDAQ:CMND) last issued its quarterly earnings results on Monday, March 18th. The company reported ($0.90) EPS for the quarter.

Hedge Funds Weigh In On Clearmind Medicine

A hedge fund recently bought a new stake in Clearmind Medicine stock. Warberg Asset Management LLC purchased a new stake in shares of Clearmind Medicine Inc. (NASDAQ:CMND) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 220,000 shares of the company’s stock, valued at approximately $35,000. Warberg Asset Management LLC owned about 3.14% of Clearmind Medicine at the end of the most recent quarter. 96.05% of the stock is currently owned by institutional investors.

Clearmind Medicine Company Profile

Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.